Drug Development Pipeline
Back to the Drug Development Pipeline
TOBI® and BETHKIS® are aerosolized forms of the antibiotic tobramycin, which is used to treat people with CF who are chronically infected with Pseudomonas aeruginosa.
The FDA approved TOBI® in 1997 and BETHKIS® 2012 .
The TOBI® program was sponsored by Novartis Pharmaceuticals and funded by the Cystic Fibrosis Foundation. The BETHKIS® program was sponsored by Cornerstone Therapeutics. Both programs were conducted within the Therapeutics Development Network.
Recent Inhaled Tobramycin Studies
Completed with Results
Early Pseudomonas Infection Control (EPIC) (EPIC-001)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More